Taladegib is currently being investigated in a phase II clinical trial (NCT05199584) involving patients with solid tumors and PTCH1 loss of function mutations, which is a common mutation in SHH-activated medulloblastomas. The gene discussed is PTCH1; the disease is medulloblastoma.